What is the optimal (neo)adjuvant strategy of extremity high-risk soft tissue sarcomas (ESTS)?

AbstractCurrently, the standard treatment for extremity high-risk soft tissue sarcomas (ESTS) combines surgery and pre- or post-op radiation therapy (RT). In some selected cases, chemotherapy (CT) is incorporated into the therapeutic algorithm as a neoadjuvant approach to enable conservative management. Given the risk of local or metastatic relapse, this paper discusses the potential benefits of CT and RT in high-grade ESTs. The role of adjuvant chemotherapy in addition to neoadjuvant CT, the prognostic value of the pathological response to neoadjuvant treatment, and the role for an adjuvant"boost" following resection after pre-operative radiotherapy will be discussed.
Source: Medical Oncology - Category: Cancer & Oncology Source Type: research